Hitachi Chemical Advanced Therapeutics Solutions (HCATS), a U.S. subsidiary of Hitachi Chemical Co., Ltd. that engages in contract manufacturing and manufacturing development of cell therapy products, and Ori Biotech, an innovator in cell and gene therapy (CGT) manufacturing, have entered into a joint development agreement to develop and commercialize technology solutions specific to the CGT industry.

Robert Preti, president and chief executive officer, HCATS, said, “Combining HCATS’ experience in manufacturing and development with Ori Biotech’s proprietary technology platform and innovative approach allows both parties to better address the increasingly critical manufacturing needs of CGT developers. Using our 20 years of manufacturing experience to help advance Ori’s novel technology furthers our leadership in addressing the industry’s manufacturing challenges and accelerates the process of delivering our clients’ therapeutics to patients in need. We look forward to partnering with Ori and are confident this collaboration will help drive innovation throughout the industry.”
 
Jason Foster, chief executive officer, Ori Biotech, said, “Our partnership with HCATS provides us an exciting opportunity to further develop and tailor our innovative CGT manufacturing platform technology for use in the real world.”